SM
BNTC icon

Sabby Management’s Benitec Biopharma BNTC Stock Holding History

Sabby Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-698
Closed -$75K – 116
2020
Q3 		$75K Hold
698
– – 0.01% 122
2020
Q2 		$94K Sell
698
-149
-18% -$20.1K 0.02% 83
2020
Q1 		$85K Sell
847
-3,792
-82% -$443K 0.04% 69
2019
Q4 		$603K Sell
4,639
-716
-13% -$108K 0.17% 29
2019
Q3 		$971K Buy
+5,355
New +$984K 0.52% 22
2017
Q1 		– Sell
-998
Closed -$389K – 272
2016
Q4 		$389K Sell
998
-79
-7% -$30.1K 0.02% 214
2016
Q3 		$385K Sell
1,077
-278
-21% -$115K 0.01% 241
2016
Q2 		$438K Sell
1,355
-300
-18% -$119K 0.02% 217
2016
Q1 		$739K Sell
1,655
-687
-29% -$505K 0.04% 183
2015
Q4 		$2.38M Buy
2,342
+361
+18% +$498K 0.13% 109
2015
Q3 		$3.11M Buy
+1,981
New +$3.7M 0.13% 122

Other funds holding BNTC

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Sabby Management's BNTC Position: Q4 2020 in Review

Sabby Management sold out of Benitec Biopharma (BNTC) in Q4 2020, closing a stake of 698 shares — an estimated $75K sold.

Sabby Management first reported a position in BNTC in Q3 2015 and held it in 11 quarters. The position peaked at $3.11M in Q3 2015. 12 funds tracked by Wall St. Rank hold BNTC as of Q4 2020.

  • Sabby Management reported no remaining Benitec Biopharma position as of Q4 2020 after selling out during the quarter.
  • Sabby Management sold 698 Benitec Biopharma shares in Q4 2020, an estimated $75K.
  • Sabby Management first reported a position in Benitec Biopharma in Q3 2015 and held it in 11 quarters.
  • Sabby Management's Benitec Biopharma position peaked at $3.11M in Q3 2015.
  • 12 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.